<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Mol. Psychiatry?><?submitter-system nihms?><?submitter-userid 8092967?><?submitter-authority eRA?><?submitter-login mvawter?><?submitter-name Marquis PHILIP Vawter?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9607835</journal-id><journal-id journal-id-type="pubmed-jr-id">20545</journal-id><journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id><journal-title-group><journal-title>Molecular psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1359-4184</issn><issn pub-type="epub">1476-5578</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">4990004</article-id><article-id pub-id-type="pmid">23459468</article-id><article-id pub-id-type="doi">10.1038/mp.2013.11</article-id><article-id pub-id-type="manuscript">nihpa805086</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sellgren</surname><given-names>CM</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">14</xref></contrib><contrib contrib-type="author"><name><surname>Kegel</surname><given-names>ME</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">14</xref></contrib><contrib contrib-type="author"><name><surname>Bergen</surname><given-names>SE</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ekman</surname><given-names>CJ</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Olsson</surname><given-names>S</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Larsson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vawter</surname><given-names>MP</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Backlund</surname><given-names>L</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sullivan</surname><given-names>PF</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Sklar</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Smoller</surname><given-names>JW</given-names></name><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Magnusson</surname><given-names>PKE</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hultman</surname><given-names>CM</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Walther-Jallow</surname><given-names>L</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Svensson</surname><given-names>CI</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lichtenstein</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schalling</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Engberg</surname><given-names>G</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Erhardt</surname><given-names>S</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Land&#233;n</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A13">13</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden</aff><aff id="A2"><label>2</label>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden</aff><aff id="A3"><label>3</label>Section of Psychiatry, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden</aff><aff id="A4"><label>4</label>Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine School of Medicine, Irvine, CA, USA</aff><aff id="A5"><label>5</label>Neurogenetics Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden</aff><aff id="A6"><label>6</label>Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden</aff><aff id="A7"><label>7</label>Department of Genetic and Psychiatry, University of North Carolina, Chapel Hill, NC, USA</aff><aff id="A8"><label>8</label>Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A9"><label>9</label>Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetics, Research, Massachusetts General Hospital, Boston, MA, USA</aff><aff id="A10"><label>10</label>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA</aff><aff id="A11"><label>11</label>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA</aff><aff id="A12"><label>12</label>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden</aff><aff id="A13"><label>13</label>The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden</aff><author-notes><corresp id="FN1">Correspondence: Professor M Land&#233;n, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg SE-413 45, Sweden. <email>mikael.landen@neuro.gu.se</email></corresp><fn id="FN2" fn-type="equal"><label>14</label><p>These two authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>25</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>05</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>8</month><year>2016</year></pub-date><volume>19</volume><issue>3</issue><fpage>334</fpage><lpage>341</lpage><!--elocation-id from pubmed: 10.1038/mp.2013.11--><permissions><license license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><abstract><p id="P1">Elevated cerebrospinal fluid (CSF) levels of the glia-derived <italic>N</italic>-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder. Here, we conducted a genome-wide association study based on CSF KYNA in bipolar disorder and found support for an association with a common variant within 1p21.3. After replication in an independent cohort, we linked this genetic variant&#8212;associated with reduced <italic>SNX7</italic> expression&#8212;to positive psychotic symptoms and executive function deficits in bipolar disorder. A series of post-mortem brain tissue and <italic>in vitro</italic> experiments suggested <italic>SNX7</italic> downregulation to result in a caspase-8-driven activation of interleukin-1&#946; and a subsequent induction of the brain kynurenine pathway. The current study demonstrates the potential of using biomarkers in genetic studies of psychiatric disorders, and may help to identify novel drug targets in bipolar disorder.</p></abstract></article-meta></front><body><sec sec-type="intro" id="S1"><title>INTRODUCTION</title><p id="P2">Elevation of brain kynurenic acid (KYNA) is a consistently found biochemical aberration in schizophrenia and bipolar disorder (BD).<sup><xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R7" ref-type="bibr">7</xref></sup> Brain KYNA is mainly produced in astrocytes as an end-metabolite of the kynurenine pathway of tryptophan metabolism. This pathway is highly inducible by inflammatory stimuli,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> and we have previously reported that cerebrospinal fluid (CSF) levels of the proinflammatory cytokine interleukin (IL)-1&#946; are markedly increased in patients with BD or schizophrenia, although the majority of other cytokines measured in this study were undetectable.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup></p><p id="P3">KYNA is a neuroactive metabolite that antagonizes the glycine co-agonist site of the <italic>N</italic>-methyl-D-aspartic acid receptor (NMDAR).<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Administration of synthetic NMDAR antagonists causes psychotic symptoms in healthy individuals,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> and exacerbates psychotic features in patients with schizophrenia.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Psychotic symptoms are core features of schizophrenia, and more than half of patients with BD will experience psychosis in their lifetime.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Supporting that KYNA might be specifically involved in the pathophysiology underlying psychotic symptoms, we have found higher levels of CSF KYNA in BD-I patients with a history of psychosis compared with those who had never experienced psychosis.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> KYNA also noncompetitively antagonizes the cholinergic &#945;7 nicotinic receptor, and animal studies indicate that increased brain KYNA might cause cognitive deficits.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> In rats, increased brain KYNA causes behavioral responses analogous to impaired set-shifting in humans,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> an index of executive function. Set-shifting dysfunction as measured by the trail making test (TMT) is indeed a feature of schizophrenia and euthymic BD,<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> especially in BD patients with a history of psychosis.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><p id="P4">Family history is the strongest risk factor for BD, but an important obstacle for progress in psychiatric genetics is that psychiatric syndromes&#8212;based solely on symptom clustering&#8212;do not necessarily reflect specific underlying biological dysfunctions and may be insufficient to delineate heritable phenotypes.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Indeed, epidemiological and molecular genetic studies have blurred the diagnostic boundary between schizophrenia and BD by demonstrating that these disorders have partly shared genetic causes.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Complementary approaches to unearth causal genetic mutations are therefore needed. One approach is to focus on biomarkers, that is, measurable key components in biological pathways between genotype and disease.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> For this purpose, the use of CSF KYNA may be particularly rewarding given its biological links to distinct subdomains of pathology present in both BD and schizophrenia.</p><p id="P5">In this study of euthymic BD patients, we found CSF IL-1&#946; and KYNA to be associated with a history of psychosis and set-shifting impairment. CSF levels of KYNA were also strongly associated with the dopamine metabolite homovanillic acid (HVA). We conducted a genome-wide association study (GWAS) against CSF levels of KYNA in BD that revealed a genome-wide significant association with the single-nucleotide polymorphism (SNP) rs10158645 within 1p21.3, a finding that was replicated in an independent cohort of BD patients. Furthermore, we analyzed this SNP in relation to CSF HVA, a history of psychosis (followed by a replication in a large data set of 565 BD patients) and set-shifting ability. As the minor allele in rs10158645 was associated with decreased expression of <italic>sorting nexin 7</italic> (<italic>SNX7</italic>), we attempted to decipher the biochemical chain of events using a multipronged approach including causal inference analyses of clinical data, post-mortem data and cell culture studies. These experiments converged on the proposal that decreased <italic>SNX7</italic> expression is linked to increased CSF KYNA concentration and ultimately psychosis and set-shifting difficulties in BD through caspase-8-driven activation of IL-1&#946;.</p></sec><sec sec-type="materials|methods" id="S2"><title>MATERIALS AND METHODS</title><p id="P6">The study was approved by the institutional review board of the Karolinska Institutet. Informed consent was obtained from all included subjects.</p><sec id="S3"><title>Clinical data sets (I&#8211;IV)</title><p id="P7">All patient data were collected from Swedish euthymic BD patients in a long-term follow-up program. The diagnostic procedure has been outlined in detail previously.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> In addition to the collected research data, we also performed medical chart reviews for the patients in data sets I, II and III, and in some cases interviews with the treating physician, to assure the diagnostic accuracy (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). If not specified in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>, all analyses included all subjects for whom data were available (the numbers vary because not all patients volunteered to undertake all investigations). The general population controls were randomly selected by Statistics Sweden (except for the controls used in the analyses of CSF IL-1&#946; who were healthy volunteers collected at Link&#246;ping University Hospital in Sweden). Further descriptions of the data sets, as well as details of CSF collection and analyses, are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. The <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> also contains a table describing the main analyses in relation to the different cohorts (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S1</xref>). Experienced psychologists performed the neuropsychological assessments, using Delis&#8211;Kaplan Executive Function System. To obtain a sensitive measure of set-shifting, we employed TMT of Delis&#8211;Kaplan Executive Function System and extracted the total time taken for Combined Letter/Number Switching minus the Combined Number Sequencing+Letter Sequencing, that is, &#8216;switching cost&#8217;. Raw contrast scores were transformed into age-corrected scaled contrast scores based on normative data in which an achievement score of 10 represents the mean in each age group.<sup><xref rid="R23" ref-type="bibr">23</xref></sup></p></sec><sec id="S4"><title>Genotyping and quality control</title><p id="P8">Whole-genome genotyping in data set II, as well as in controls, was done on the Affymetrix 6.0 array (Santa Clara, CA, USA) at the Broad Institute in Boston, MA, USA. Subjects in sample IV were genome-wide genotyped using the Affymetrix 6.0 chip or the Illumina OmniExpress chip (Illumina, Inc., San Diego, CA, USA). Procedures for genotyping and quality control have been provided in prior publications.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> Patients in sample III were genotyped for rs10158645 on a 7900HT Fast Real-Time PCR System Instrument by using allele-specific TaqMan MGB probes labeled with fluorescent dyes FAM and VIC (Applied Biosystems, Foster City, CA, USA) according to the manufacturer&#8217;s protocols. Allelic discrimination was performed with the ABI PRISM 7900HT SDS and the SDS 2.2.1 program (Applied Biosystems) in 384-well format with 9 negative controls distributed in each plate. The rs10158645 genotype distribution did not depart from Hardy&#8211;Weinberg equilibrium. Ten percent of the samples were run in duplicate to verify genotyping results.</p></sec><sec id="S5"><title>Expression quantitative trait data and coexpression patterns (data sets V&#8211;IX)</title><p id="P9">Data set V was based on fibroblast data from the MuTHER resource and assessed through the Genevar database (GENe Expression VARiation, The Wellcome Trust Sanger Institute; <ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/resources/software/genevar">http://www.sanger.ac.uk/resources/software/genevar</ext-link>). The replication data set (VI) was based on lymphoblastoid cell lines from all unrelated subjects of the HapMap3 population (SNPexp v1.2; <ext-link ext-link-type="uri" xlink:href="http://app3.titan.uio.no/biotools/help.php?app=snpexp">http://app3.titan.uio.no/biotools/help.php?app=snpexp</ext-link>). For the lncRNA (<italic>RP5-896L10.1</italic>) and <italic>SNX7</italic> coexpression analysis (data set VII), we used a sample from the Functional Genomics Laboratory at University of California, Irvine (MPV) in which RNA-sequencing analyses for both coding and noncoding transcripts were assayed from 32 dorsolateral prefrontal cortex samples obtained from healthy volunteers. To study coexpression of <italic>SNX7</italic>, <italic>CASP8</italic>, <italic>IL1B</italic> and <italic>TDO2</italic> (data set VIII), we used a post-mortem brain tissue collection deposited in the Braincloud database (<ext-link ext-link-type="uri" xlink:href="http://braincloud.jhmi.edu">http://braincloud.jhmi.edu</ext-link>). Through an authorized access (MPV), we obtained data on 272 tissue homogenates of dorsolateral prefrontal cortex gray matter (BA46/9) from healthy donors. The sample and the methods have been previously described.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Levels of dorsolateral prefrontal cortex (BA46) <italic>CASP8</italic> mRNA in relation to psychosis in BD (data set IX) were studied using data obtained from the Stanley Medical Research Institute database (<ext-link ext-link-type="uri" xlink:href="www.stanleygenomics.org">www.stanleygenomics.org</ext-link>).</p></sec><sec id="S6"><title>Human astrocyte cultures</title><p id="P10">Human embryonic primary cortical astrocytes were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA) and cultured according to the manufacturer&#8217;s recommendations. Before experiments, characterization of the cells was performed to rule out the presence of microglia or neurons in the culture. All experiments were performed on cells in passage 4. Cells were serum starved (0.02% fetal bovine serum and 0.01% growth supplement mix) for 24 h before experiments. Cytokines and antibodies used in the cell studies are described in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>.</p></sec><sec id="S7"><title>Quantitative real-time PCR</title><p id="P11">Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer&#8217;s protocol. Quantitative PCR was performed using the Fast Real-Time PCR System (Applied Biosystems). See <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> for a complete description of used methods.</p></sec><sec id="S8"><title>Western blot analyses</title><p id="P12">Total protein was extracted using ice-cold lysis buffer. The membrane was incubated with primary antibody against tryptophan 2,3-dioxygenase-2 (TDO2; 1:2000) or indoleamine 2,3-dioxygenase 1 (IDO1; 1:1000) overnight, and then incubated with secondary antibody for 1 h in room temperature. Protein levels were normalized to &#946;-actin (1:5000) and blots were analyzed using Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA). See <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> for further details.</p></sec><sec id="S9"><title>Analysis of KYNA in cell culture supernatants</title><p id="P13">Cell culture supernatants were collected and immediately frozen on dry ice and kept in &#8722; 20 &#176;C until analysis. Analyses of KYNA are described in <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>.</p></sec><sec id="S10"><title>Statistics</title><p id="P14">The primary analysis in the GWAS was a linear regression of CSF KYNA residuals on single-SNP allele dosage. &#8216;Genome-wide significance&#8217; was set to <italic>P</italic>&lt;5 &#215; 10<sup>&#8722;8</sup>. Additional analyses with the first four multidimensional scaling components as covariates to control for population substructure were also performed. In the correlation analyses, &#8216;<italic>r</italic>&#8217; refers to Pearson&#8217;s correlation coefficient if not otherwise specified. The sample size chosen in the replication of the GWAS was based on a power of 95%. The assumptions of each test were checked. All reported <italic>P</italic>-values are two sided. All analyses were done using the statistical software programs R (R Development Core Team, Vienna, Austria), IBM SPSS Statistics 20.0 (IBM SPSS, Chicago, IL, USA), the script PROCESS for SPSS (percentile bootstrap = 20 000) and Graph-Pad prism 6.0 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">http://www.graphpad.com/</ext-link>).</p></sec></sec><sec sec-type="results" id="S11"><title>RESULTS</title><sec id="S12"><title>CSF biomarkers and clinical endophenotypes in BD</title><p id="P15">CSF IL-1&#946; concentrations in male euthymic BD patients (<italic>N</italic> = 27) were derived from data set I. Patients with a history of psychosis (<italic>N</italic> = 16) had significantly increased CSF IL-1&#946; concentrations compared with patients without (<italic>N</italic> = 11), but both groups displayed increased IL-1&#946; levels compared with healthy controls (<italic>N</italic> = 30; <xref rid="F1" ref-type="fig">Figure 1a</xref>). The control group was significantly younger than the patient groups but CSF IL-1&#946; concentration was not associated with age, and adjusted analyses gave similar results (data not shown). Body mass index, smoking status and weekly alcohol consumption were also independent of CSF IL-1&#946; concentration (data not shown). Comparison of pharmacological treatments between psychotic and nonpsychotic bipolar patients suggested an equal distribution (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S2</xref>), and no significant effects of any pharmacological treatment on IL-1&#946; concentration could be detected (data not shown).</p><p id="P16">In conjunction with the lumbar puncture, 16 of the 27 BD patients volunteered for cognitive testing with TMT to evaluate executive functions in terms of set-shifting ability. The median CSF IL-1&#946; concentration was significantly higher in patients who scored below the mean standard score of 10 on TMT (Switching vs Combined Number Letter Sequencing) compared with patients scoring &#8805; 10 (<xref rid="F1" ref-type="fig">Figure 1b</xref>). As a putative influx of peripheral IL-1&#946; to the brain may influence central levels of IL-1&#946;, we tested for a possible confounding effect of peripheral inflammation by measuring serum high-sensitivity C-reactive protein in these patients. High-sensitivity C-reactive protein covaries with serum concentration of IL-1&#946;,<sup><xref rid="R26" ref-type="bibr">26</xref></sup> and is associated with cognitive impairment.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Nevertheless, a significant negative correlation between CSF IL-1&#946; concentration and set-shifting ability remained, even after a partial correlation analyses with high-sensitivity C-reactive protein as covariate (<xref rid="F1" ref-type="fig">Figure 1c</xref>).</p><p id="P17">We measured CSF KYNA concentrations in a cohort of genotyped euthymic BD patients (<italic>N</italic> = 76, data set II) and randomly selected controls from the general population (<italic>N</italic> = 46). An effect of age on CSF KYNA concentration was observed in patients as well as in controls (&#946; (unstandardized coefficient) = 0.025, <italic>P</italic> = 2 &#215; 10<sup>&#8722;3</sup>, &#946; = 0.031, <italic>P</italic> = 7 &#215; 10<sup>&#8722;6</sup>, respectively). To account for potential age confounding, we henceforth used the residuals from a linear regression of age vs CSF KYNA when age was indicated as a potential confounder. In patients, CSF KYNA concentration was independent of bipolar subtype (<italic>P</italic> = 0.63). Nor did age-adjusted CSF KYNA concentration correlate to lifetime number of mood episodes (<italic>P</italic> = 0.54), body mass index, smoking status or weekly alcohol consumption (data not shown). The 36 patients with a history of psychosis but not the 40 patients without such a history had a significantly increased mean CSF KYNA concentration compared with the control group. Moreover, patients with a history of psychosis had significantly higher CSF KYNA concentration than patients without a history of psychosis (<xref rid="F2" ref-type="fig">Figure 2a</xref>). Comparing pharmacological treatments between these groups, only lithium use was more common in the group with a history of psychosis (Fisher&#8217;s exact test; <italic>P</italic> = 0.034). However, the use of lithium was not associated with CSF KYNA concentration (<italic>P</italic> = 0.75). For a complete list of ongoing pharmacological treatments in data set II, see <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S3</xref>.</p><p id="P18">Of the 76 euthymic bipolar patients in data set II, 51 volunteered for cognitive testing with TMT. In line with the findings regarding IL-1&#946;, the mean CSF KYNA concentration was significantly higher in patients who scored &lt;10 (<italic>N</italic> = 26) compared with patients scoring &#8805; 10 (<italic>N</italic> = 25; <xref rid="F2" ref-type="fig">Figure 2b</xref>). Comparison of pharmacological treatments between the groups suggested an equal distribution (data not shown).</p><p id="P19">CSF concentration of HVA was successfully determined in 72 of the 76 patients in data set II and in 45 of the 46 controls. A strong positive correlation to CSF KYNA was observed in patients (<xref rid="F2" ref-type="fig">Figure 2c</xref>). Similar to the analysis of CSF KYNA, patients with a history of psychosis had a significantly higher mean CSF HVA concentration than healthy controls or nonpsychotic BD patients, where no significant difference in CSF HVA concentration was seen (<xref rid="F2" ref-type="fig">Figure 2d</xref>).</p></sec><sec id="S13"><title>Common genetic variants and CSF biomarkers in BD</title><p id="P20">To elucidate the genetic variability underlying individual levels of CSF KYNA in BD, we conducted a GWAS against CSF KYNA concentrations using data set II. Despite the modest sample size (<italic>N</italic> = 76), one SNP (rs10158645), located within 1p21.3, reached genome-wide statistical significance in relation to CSF KYNA (&#946; = 1.07, <italic>r</italic> = 0.58, <italic>P</italic> = 2.6 &#215; 10<sup>&#8722;8</sup>, minor allele frequency = 0.15; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1A</xref> (MH-plot), <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1B</xref> (QQ-plot), <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S1C&#8211;E</xref>). Background characteristics were similar between carriers and noncarriers of the minor allele in rs10158645 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S4</xref>). Neither the total number of mood episodes nor the number of depressive episodes were associated with rs10158645 genotype (data not shown). To control for population substructure, we also analyzed the association using the first four multidimensional scaling components as covariates. In line with a low grade of genetic diversity (all subjects and their parents were born in Sweden), this yielded a similar result as the unadjusted analysis (&#946; = 1.08, <italic>P</italic> = 4.3 &#215; 10<sup>&#8722;8</sup>; for multidimensional scaling plots see <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S2A and B</xref>.</p><p id="P21">We then measured CSF concentrations of KYNA and genotyped rs10158645 (minor allele frequency = 0.15) in an independent cohort of 18 female and 12 male Swedish BD patients (data set III; median age 39 years, interquartile range = 22). In this data set, 13 patients had a BD-I diagnosis and 17 a BD-II diagnosis. Similar to the analysis in data set II, we observed a strong positive correlation between the minor G allele in rs10158645 and CSF KYNA concentration (<xref rid="T1" ref-type="table">Table 1</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S3</xref>).</p><p id="P22">Analogous to results in BD patients, a significant effect of the minor G allele of rs10158645 on CSF KYNA concentration was also seen in the 46 healthy controls (&#946; = 0.43, <italic>r</italic> = 0.31, <italic>P</italic> = 0.036; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4</xref>), although none of the controls carried the G/G genotype. Including an adjustment for population stratification gave a similar result (&#946; = 0.50, <italic>P</italic> = 0.021). The allele distribution in rs10158645 did not differ when comparing all BD patients with controls (<italic>N</italic> = 123, odds ratio = 1.60, 95% confidence interval: 0.68&#8211;3.72; <italic>P</italic> = 0.30), but the risk allele was significantly overrepresented in bipolar subjects with psychosis compared with controls (<italic>N</italic> = 83, odds ratio = 2.83, 95% confidence interval: 1.10&#8211;7.23; <italic>P</italic> = 0.031).</p></sec><sec id="S14"><title>Follow-up studies of rs10158645: psychosis and set-shifting ability</title><p id="P23">The minor allele of rs10158645 was associated with psychotic symptoms in data set II (odds ratio = 3.98, <italic>P</italic> = 0.011; <xref rid="T1" ref-type="table">Table 1</xref>). We then studied the effect of rs1018645 genotype on psychosis using an independent data set of 565 BD patients without CSF data (data set IV). Again, we tested the effect of the rs10158645 genotype on risk of psychosis and observed an increased risk of psychosis for patients carrying the minor G allele (odds ratio = 1.50, <italic>P</italic> = 0.020; <xref rid="T1" ref-type="table">Table 1</xref>).</p><p id="P24">To achieve sufficient power, we tested the effect of rs10158645 on set-shifting ability combining all patients in data sets II and IV with TMT data (<italic>N</italic> = 89). Carriers of the minor allele scored lower than the mean standard score of 10 (<italic>N</italic> = 29, <italic>M</italic> = 8.93 &#177; 0.47), whereas noncarriers scored close to 10 (<italic>N</italic> = 60, <italic>M</italic> = 10.1 &#177; 0.30; <italic>P</italic> = 0.035), indicating diminished cognitive flexibility in carriers of the minor allele.</p></sec><sec id="S15"><title>Causal mediation analyses</title><p id="P25">The minor allele in rs10158645 was associated with increased CSF HVA concentration in data set II (&#946; = 0.54, <italic>P</italic> = 7.3 &#215; 10<sup>&#8722;7</sup>; <xref rid="T1" ref-type="table">Table 1</xref>). As previous experimental studies showed that elevation of rat brain KYNA levels is associated with activation of midbrain dopamine firing,<sup><xref rid="R28" ref-type="bibr">28</xref></sup> we applied a statistical mediational model with rs10158645 allele frequency as the causal variable, CSF KYNA as the mediator and CSF HVA as the outcome variable. The same cases (<italic>N</italic> = 72) were used in all analyses, and the same covariate (age) were used in all equations. Using a nonparametric bootstrap method,<sup><xref rid="R29" ref-type="bibr">29</xref></sup> the indirect effect that estimates the amount of mediation was significant, whereas the direct effect was smaller and nonsignificant (<xref rid="T1" ref-type="table">Table 1</xref>). To study possible reverse causal effects we interchanged the mediator and outcome variable. This also suggested a significant indirect effect but now with a significant and larger direct effect, hereby suggesting a better fit of the first model. Thus, these mediation analyses propose that the causal minor allele in rs10158645 increases CSF HVA via KYNA, in agreement with previous experimental studies.</p><p id="P26">To study whether the association of KYNA on psychosis in BD was driven by an effect on dopaminergic transmission, we tested a mediation model in which CSF KYNA was the causal variable, CSF HVA the mediator and psychosis the outcome variable. Again, we included age as a covariate, and used the same 72 subjects. This model gave a significant indirect effect with a nonsignificant direct effect (<xref rid="T1" ref-type="table">Table 1</xref>), suggesting that the increased risk of psychosis caused by elevated levels of KYNA was mediated by dopamine neurotransmission.</p></sec><sec id="S16"><title>The identified genetic locus and variation in gene expression</title><p id="P27">We searched the MuTHER resource<sup><xref rid="R30" ref-type="bibr">30</xref></sup> (fibroblast data, data set V) regarding the effect of rs10158645 genotype on gene expression (the search by default set to a search of +/&#8722; 1 Mb, that is, <italic>cis</italic>-effects). The strongest association was found between the minor allele in rs10158645 and a decreased expression of the nearby gene <italic>SNX7</italic> (<italic>P</italic> = 2.0 &#215; 10<sup>&#8722;4</sup>). We then studied the effect of rs10158645 genotype on <italic>SNX7</italic> expression in a replication data set (<italic>N</italic> = 198, data set VI), based on data from another cell type (lymphoblastoid cell lines) and again observed a significant and similar association (<italic>P</italic> = 9.6 &#215; 10<sup>&#8722;3</sup>).</p><p id="P28">rs10158645 is located in an intron of <italic>RP5-896L10.1</italic>, a long noncoding RNA (lncRNA) gene that is predominately expressed in the brain, and ~ 2 kB from a predicted enhancer region. Although sparsely studied, lncRNA has recently been shown to regulate the expression of nearby genes, that is, <italic>cis</italic>-effects.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Utilizing tissue from 32 post-mortem human brains (data set VII), we found an inverse coexpression of <italic>RP5-896L10.1</italic> and <italic>SNX7</italic> (<italic>r</italic> = &#8722; 0.23; <italic>P</italic> = 0.030), suggesting that the observed <italic>cis</italic>-effect of rs10158645 on <italic>SNX7</italic> was mediated by increased <italic>RP5-896L10</italic> expression. Against this background, we deemed that the most likely functionality of the identified locus was to regulate <italic>SNX7</italic> expression.</p></sec><sec id="S17"><title>SNX7 downstream signaling and KYNA synthesis</title><p id="P29">The SNX family proteins function in diverse intracellular trafficking and signaling processes.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Although SNX7 is rarely studied, a recent report showed that a downregulation of <italic>SNX7</italic> increases caspase-8 protein levels in hepatocytes, most likely by inducing the degradation of the short form of c-FLIP at the riboptosome platform.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Caspase-8 has a pivotal role for microglia activation by cleaving pro-IL-1&#946; into its biologically active structure,<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> and the brain kynurenine pathway almost exclusively plays out in microglia and astrocytes. The first step of the pathway, that is, the conversion of tryptophan to <italic>N</italic>-formylkynurenine by the enzyme IDO1 or the complementary enzyme TDO2, are proposed to be critically regulated by immune signaling.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p id="P30">First, we investigated whether IL-1&#946; induces TDO2 and/or IDO1 in human astrocytes, the main producer of KYNA in the brain. Stimulation with IL-1&#946; increased the expression of both <italic>IDO1</italic> and <italic>TDO2</italic> mRNA, but only increased protein levels of TDO2. Cells stimulated with IL-1&#946; also showed 4 times higher KYNA concentrations compared with vehicle-treated cells (see <xref rid="F3" ref-type="fig">Figure 3</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S5&#8211;S9</xref> for details). Our results, suggesting IL-1&#946;-driven TDO2 upregulation to increase KYNA synthesis, are in line with a recent report showing a similar mechanism in human endometrioma stromal cells.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p><p id="P31">We performed analyses of human brain mRNA coexpression data to further evaluate the importance of <italic>SNX7</italic> downregulation for IL-1&#946;-driven induction of TDO2. In a sample of 272 tissue homogenates of prefrontal gray matter from healthy donors (data set VIII), we observed a strong inverse correlation between <italic>SNX7</italic> and <italic>TDO2</italic> expression (<italic>r</italic> = &#8722; 0.56; <italic>P</italic> = 1 &#215; 10<sup>&#8722;23</sup>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S10A</xref>). In concordance with previous results from hepatocytes, we further found a strong inverse coexpression of <italic>SNX7</italic> and <italic>CASP8</italic> (<italic>r</italic> = &#8722; 0.44; <italic>P</italic> = 2 &#215; 10<sup>&#8722;14</sup>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S10B</xref>). Notably, we also found that <italic>CASP8</italic> expression was significantly increased in BD with psychotic features compared with BD without psychotic features (fold change = 1.15; 99% confidence interval: 1.04&#8211;1.20) using mRNA expression in a post-mortem sample of 105 BD patients (data set IX). Furthermore, consistent with our <italic>in vitro</italic> data from human astrocytes, we observed a strong correlation between <italic>IL-1</italic>&#946; and <italic>TDO2</italic> expression (<italic>r</italic> = 0.44; <italic>P</italic> = 5 &#215; 10<sup>&#8722;14</sup>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S10C</xref>). This accords previous studies showing that <italic>TDO2</italic> mRNA and protein levels are increased in schizophrenia and in BD patients with psychotic symptoms, whereas IDO1 levels are unaltered.<sup><xref rid="R37" ref-type="bibr">37</xref></sup></p></sec></sec><sec sec-type="discussion" id="S18"><title>DISCUSSION</title><p id="P32">This is to the best of our knowledge the first study of a heritable psychiatric disorder that at a molecular level attempts to link a GWAS finding, biochemical aberrations and clinical presentation. Our results suggest that a risk allele within 1p21.3 gives rise to a series of immune-related cascades that elevate brain KYNA levels and contribute to psychotic symptoms as well as persistent executive function deficits in BD. Our results align with previous experimental and clinical studies suggesting that KYNA, sharing both pharmacological and neurobehavioral effects with ketamine and phencyclidine, induces psychotomimetic effects and cognitive deficits.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup></p><p id="P33">The role of KYNA in psychosis converges with multiple lines of evidence implicating an increased dopaminergic drive in mania and psychosis.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> Experimental studies have shown that elevation of rat brain KYNA levels with the same order of magnitude as observed in BD is associated with increased firing of midbrain dopaminergic neurons.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R40" ref-type="bibr">40</xref></sup> These experimental findings corroborate our present results, showing higher levels of CSF HVA in psychotic BD patients compared with nonpsychotic BD patients, as well as a positive correlation between CSF KYNA and HVA. The KYNA-driven activation of dopamine transmission, also supported by our statistical causal mediation analyses, validates the classical view that dopamine contributes to psychotic symptoms in BD.</p><p id="P34">Persistent cognitive impairment is increasingly recognized as an important and heritable feature of BD.<sup><xref rid="R41" ref-type="bibr">41</xref></sup> NMDAR as well as cholinergic &#945;7 nicotinic receptor have an established role in cognitive functions.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup> The present study demonstrates for the first time in humans that KYNA, an endogenous antagonist at both receptors, is associated with impaired cognitive flexibility in terms of decreased set-shifting ability. In support of a more generalized action of brain KYNA, cognitive enhancers such as D-serine/glycine transporter inhibitors or galantamine target the glycine site of the NMDAR or the cholinergic &#945;7 nicotinic receptor, respectively. Indeed, mice with reduced glycine affinity of the NMDAR display behavioral set-shifting impairments that can be reversed by D-serine,<sup><xref rid="R43" ref-type="bibr">43</xref></sup> and blockade of glycine transporters promotes set-shifting tasks in rats.<sup><xref rid="R44" ref-type="bibr">44</xref></sup> In addition, KYNA-induced impairment in set-shifting ability in rats is reversed by galantamine.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> This suggests that D-serine/glycine transporter inhibitors or galantamine might prove principally useful to counteract cognitive dysfunction associated with high levels of KYNA.</p><p id="P35">In the present study, the genetic variation within 1p21.3 was also associated with increased risk of psychosis and cognitive impairments in BD. Gene expression data suggested that this genetic risk allele results in decreased expression of the <italic>SNX7</italic>. Our post-mortem and <italic>in vitro</italic> data point toward a caspase-8-driven activation of IL-1&#946; that, through TDO2 induction, increases the astrocytic production of KYNA, eventually giving rise to psychotic symptoms and cognitive dysfunction in BD (<xref rid="F4" ref-type="fig">Figure 4</xref>). It remains to be investigated whether this pertains to BD only or is a phenomenon shared with other psychiatric disorders. Clearly, glia plays an important role in a broad range of central nervous system pathologies,<sup><xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R46" ref-type="bibr">46</xref></sup> and under several of these conditions a dysregulation of the kynurenine pathway has been observed.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p id="P36">This study has some important limitations. First, as we use high-resolution phenotypic data, for example, CSF biomarkers from a meticulously clinically characterized BD cohort with a low grade of genetic diversity, our sample sizes are inevitably much smaller than in conventional psychiatric multicenter case&#8211;control GWAS. However, the successful replications, together with the results of the complementary cell and post-mortem experiments, suggest that our findings in the discovery cohort are robust. Moreover, it has been repeatedly shown that biomarkers, in comparison with clusters of co-occurring symptoms, are under more direct genetic control, and thus more tractable traits in GWAS paradigms.<sup><xref rid="R47" ref-type="bibr">47</xref>&#8211;<xref rid="R49" ref-type="bibr">49</xref></sup> Hence, genetic studies of biomarkers might be an alternative strategy for highly needed mechanistic studies of neuropsychiatric disorders, and the current study demonstrates the potential of such an approach. Second, although we demonstrate several consistent associations between molecular and clinical components, we lack conclusive data that directly tie together these individual associations to a signaling pathway that is causally related to psychosis and cognitive deficits. More specifically, we do not demonstrate a direct link between the genetic risk variant and CSF IL-&#946; levels or between CSF levels of IL-1&#946; and KYNA. Third, the analyses of SNX7 downstream signaling were performed on post-mortem tissue or using <italic>in vitro</italic> data. Studies using genetic editing in living brain cells are warranted to verify these mechanisms.</p><p id="P37">To conclude, this study offers evidence for a genetic risk allele that contributes to vulnerability for psychosis and cognitive deficits in BD through increased KYNA production. The proposed mechanism of an aberrant SNX7/caspase-8/IL-1&#946; signaling, the induction of TDO2 enzyme activity and eventually enhanced KYNA synthesis may help to identify novel drug targets for the prevention of psychotic symptoms and cognitive dysfunction in BD.</p></sec><sec sec-type="supplementary-material" id="S19"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supllementral</label><media xlink:href="NIHMS805086-supplement-Supllementral.doc" orientation="portrait" xlink:type="simple" id="d37e1097" position="anchor"/></supplementary-material></sec></body><back><ack id="S20"><p>We thank the patients who contributed to this study. We also thank clinical collaborators and facilitators for help with recruitment of participants. We are grateful to Pascal Borgstr&#246;m for assistance with the cognitive assessment and to Emil Rhenberg for statistical support. This work was supported by grants from the Swedish Medical Research Council (to Land&#233;n: K2014-62X-14647-12-51 and K2010-61P-21568-01-4; to Engberg: 2009&#8211;3068 and 2011&#8211;4789; to Erhardt: 2009&#8211;7053 and 2013&#8211;2838; to Schalling: 2011&#8211;4807 and 2013&#8211;6652; and to Svensson: 2009&#8211;3068), the Swedish foundation for Strategic Research (KF10&#8211;0039), the Swedish Brain foundation, Petrus och Augusta Hedlunds Stiftelse, &#197;hl&#233;n-stiftelsen, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet (ALF 20100305 and KID) and the Broad Institute.</p></ack><fn-group><fn fn-type="COI-statement" id="FN3"><p><bold>CONFLICT OF INTEREST</bold></p><p>The authors declare no conflict of interest.</p></fn><fn id="FN4"><p><xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> accompanies the paper on the Molecular Psychiatry website (<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/mp">http://www.nature.com/mp</ext-link>)</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><name><surname>Skogh</surname><given-names>E</given-names></name><name><surname>Lindstrom</surname><given-names>LH</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name></person-group><article-title>Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia</article-title><source>Neurosci Lett</source><year>2001</year><volume>313</volume><fpage>96</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11684348</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R</given-names></name><name><surname>Rassoulpour</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>HQ</given-names></name><name><surname>Medoff</surname><given-names>D</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name><name><surname>Roberts</surname><given-names>RC</given-names></name></person-group><article-title>Increased cortical kynurenate content in schizophrenia</article-title><source>Biol Psychiatry</source><year>2001</year><volume>50</volume><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">11600105</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Saetre</surname><given-names>P</given-names></name><name><surname>Lindstrom</surname><given-names>L</given-names></name><name><surname>Jonsson</surname><given-names>EG</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder</article-title><source>J Psychiatry Neurosci</source><year>2010</year><volume>35</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">20420770</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Larsson</surname><given-names>MK</given-names></name><name><surname>Erhardt</surname><given-names>S</given-names></name></person-group><article-title>Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice</article-title><source>J Neural Transm</source><year>2012</year><volume>119</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">21904895</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linderholm</surname><given-names>KR</given-names></name><name><surname>Skogh</surname><given-names>E</given-names></name><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><name><surname>Holtze</surname><given-names>M</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia</article-title><source>Schizophr Bull</source><year>2012</year><volume>38</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">20729465</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wonodi</surname><given-names>I</given-names></name><name><surname>Stine</surname><given-names>OC</given-names></name><name><surname>Sathyasaikumar</surname><given-names>KV</given-names></name><name><surname>Roberts</surname><given-names>RC</given-names></name><name><surname>Mitchell</surname><given-names>BD</given-names></name><name><surname>Hong</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes</article-title><source>Arch Gen Psychiatry</source><year>2011</year><volume>68</volume><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">21727251</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavebratt</surname><given-names>C</given-names></name><name><surname>Olsson</surname><given-names>S</given-names></name><name><surname>Backlund</surname><given-names>L</given-names></name><name><surname>Frisen</surname><given-names>L</given-names></name><name><surname>Sellgren</surname><given-names>C</given-names></name><name><surname>Priebe</surname><given-names>L</given-names></name><etal/></person-group><article-title>The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression</article-title><source>Mol Psychiatry</source><year>2014</year><volume>19</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">23459468</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R</given-names></name><name><surname>Bruno</surname><given-names>JP</given-names></name><name><surname>Muchowski</surname><given-names>PJ</given-names></name><name><surname>Wu</surname><given-names>HQ</given-names></name></person-group><article-title>Kynurenines in the mammalian brain: when physiology meets pathology</article-title><source>Nat Rev Neurosci</source><year>2012</year><volume>13</volume><fpage>465</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">22678511</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soderlund</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Walther-Jallow</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name><name><surname>Erhardt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder</article-title><source>J Psychiatry Neurosci</source><year>2011</year><volume>36</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">21138659</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soderlund</surname><given-names>J</given-names></name><name><surname>Schroder</surname><given-names>J</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Walther-Jallow</surname><given-names>L</given-names></name><name><surname>Karlsson</surname><given-names>H</given-names></name><etal/></person-group><article-title>Activation of brain interleukin-1beta in schizophrenia</article-title><source>Mol Psychiatry</source><year>2009</year><volume>14</volume><fpage>1069</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">19920835</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Seibyl</surname><given-names>JP</given-names></name><name><surname>Freeman</surname><given-names>GK</given-names></name><name><surname>Delaney</surname><given-names>R</given-names></name><name><surname>Bremner</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title><source>Arch Gen Psychiatry</source><year>1994</year><volume>51</volume><fpage>199</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">8122957</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahti</surname><given-names>AC</given-names></name><name><surname>Koffel</surname><given-names>B</given-names></name><name><surname>LaPorte</surname><given-names>D</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name></person-group><article-title>Subanesthetic doses of ketamine stimulate psychosis in schizophrenia</article-title><source>Neuropsychopharmacology</source><year>1995</year><volume>13</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">8526975</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunayevich</surname><given-names>E</given-names></name><name><surname>Keck</surname><given-names>PE</given-names><suffix>Jr</suffix></name></person-group><article-title>Prevalence and description of psychotic features in bipolar mania</article-title><source>Curr Psychiatry Rep</source><year>2000</year><volume>2</volume><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">11122970</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Sellgren</surname><given-names>C</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name><name><surname>Landen</surname><given-names>M</given-names></name><name><surname>Erhardt</surname><given-names>S</given-names></name></person-group><article-title>Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder</article-title><source>Bipolar Disord</source><year>2012</year><volume>14</volume><fpage>719</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">23030601</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>KS</given-names></name><name><surname>Wu</surname><given-names>HQ</given-names></name><name><surname>Schwarcz</surname><given-names>R</given-names></name><name><surname>Bruno</surname><given-names>JP</given-names></name></person-group><article-title>Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine</article-title><source>Psychopharmacology</source><year>2012</year><volume>220</volume><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">22038535</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perianez</surname><given-names>JA</given-names></name><name><surname>Rios-Lago</surname><given-names>M</given-names></name><name><surname>Rodriguez-Sanchez</surname><given-names>JM</given-names></name><name><surname>Adrover-Roig</surname><given-names>D</given-names></name><name><surname>Sanchez-Cubillo</surname><given-names>I</given-names></name><name><surname>Crespo-Facorro</surname><given-names>B</given-names></name><etal/></person-group><article-title>Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: sample comparisons and normative data</article-title><source>Arch Clin Neuropsychol</source><year>2007</year><volume>22</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">17336493</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>LN</given-names></name><name><surname>Torres</surname><given-names>IJ</given-names></name><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Frangou</surname><given-names>S</given-names></name><name><surname>Glahn</surname><given-names>DC</given-names></name><name><surname>Bearden</surname><given-names>CE</given-names></name><etal/></person-group><article-title>The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC)</article-title><source>Bipolar Disord</source><year>2010</year><volume>12</volume><fpage>351</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">20636632</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bora</surname><given-names>E</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name><name><surname>Pantelis</surname><given-names>C</given-names></name></person-group><article-title>Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study</article-title><source>J Affect Disord</source><year>2010</year><volume>127</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20231037</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szatmari</surname><given-names>P</given-names></name><name><surname>Maziade</surname><given-names>M</given-names></name><name><surname>Zwaigenbaum</surname><given-names>L</given-names></name><name><surname>Merette</surname><given-names>C</given-names></name><name><surname>Roy</surname><given-names>MA</given-names></name><name><surname>Joober</surname><given-names>R</given-names></name><etal/></person-group><article-title>Informative phenotypes for genetic studies of psychiatric disorders</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2007</year><volume>144B</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">17219386</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>P</given-names></name><name><surname>Yip</surname><given-names>BH</given-names></name><name><surname>Bjork</surname><given-names>C</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Cannon</surname><given-names>TD</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">19150704</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cross-Disorder Group of the Psychiatric Genomics C</collab><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>984</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">23933821</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottesman</surname><given-names>II</given-names></name><name><surname>Gould</surname><given-names>TD</given-names></name></person-group><article-title>The endophenotype concept in psychiatry: etymology and strategic intentions</article-title><source>Am J Psychiatry</source><year>2003</year><volume>160</volume><fpage>636</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">12668349</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homack</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Riccio</surname><given-names>CA</given-names></name></person-group><article-title>Test review: Delis-Kaplan executive function system</article-title><source>J Clin Exp Neuropsychol</source><year>2005</year><volume>27</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">16019636</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergen</surname><given-names>SE</given-names></name><name><surname>O&#8217;Dushlaine</surname><given-names>CT</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Akterin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder</article-title><source>Mol Psychiatry</source><year>2012</year><volume>17</volume><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">22688191</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colantuoni</surname><given-names>C</given-names></name><name><surname>Lipska</surname><given-names>BK</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Tao</surname><given-names>R</given-names></name><name><surname>Leek</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Temporal dynamics and genetic control of transcription in the human prefrontal cortex</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">22031444</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>AM</given-names></name><name><surname>Ellis</surname><given-names>CD</given-names></name><name><surname>Shintani</surname><given-names>A</given-names></name><name><surname>Booker</surname><given-names>C</given-names></name><name><surname>Ikizler</surname><given-names>TA</given-names></name></person-group><article-title>IL-1beta receptor antagonist reduces inflammation in hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2011</year><volume>22</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">21310819</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshi</surname><given-names>T</given-names></name><name><surname>Yamagami</surname><given-names>H</given-names></name><name><surname>Furukado</surname><given-names>S</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors</article-title><source>Eur J Neurol</source><year>2010</year><volume>17</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">20298426</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name></person-group><article-title>Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid</article-title><source>Acta Physiol Scand</source><year>2002</year><volume>175</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">11982504</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>AF</given-names></name><name><surname>Preacher</surname><given-names>KJ</given-names></name></person-group><article-title>Statistical mediation analysis with a multicategorical independent variable</article-title><source>Br J Math Stat Psychol</source><year>2013</year><volume>67</volume><fpage>451</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">24188158</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nica</surname><given-names>AC</given-names></name><name><surname>Parts</surname><given-names>L</given-names></name><name><surname>Glass</surname><given-names>D</given-names></name><name><surname>Nisbet</surname><given-names>J</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name><name><surname>Sekowska</surname><given-names>M</given-names></name><etal/></person-group><article-title>The architecture of gene regulatory variation across multiple human tissues: the MuTHER study</article-title><source>PLoS Genet</source><year>2011</year><volume>7</volume><fpage>e1002003</fpage><pub-id pub-id-type="pmid">21304890</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Orom</surname><given-names>UA</given-names></name><name><surname>Cesaroni</surname><given-names>M</given-names></name><name><surname>Beringer</surname><given-names>M</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Blobel</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Activating RNAs associate with Mediator to enhance chromatin architecture and transcription</article-title><source>Nature</source><year>2013</year><volume>494</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">23417068</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teasdale</surname><given-names>RD</given-names></name><name><surname>Collins</surname><given-names>BM</given-names></name></person-group><article-title>Insights into the PX (phox-homology) domain and SNX (sorting nexin) protein families: structures, functions and roles in disease</article-title><source>Biochem J</source><year>2012</year><volume>441</volume><fpage>39</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">22168438</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>An antiapoptotic role of sorting nexin 7 is required for liver development in zebrafish</article-title><source>Hepatology</source><year>2012</year><volume>55</volume><fpage>1985</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">22213104</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burguillos</surname><given-names>MA</given-names></name><name><surname>Deierborg</surname><given-names>T</given-names></name><name><surname>Kavanagh</surname><given-names>E</given-names></name><name><surname>Persson</surname><given-names>A</given-names></name><name><surname>Hajji</surname><given-names>N</given-names></name><name><surname>Garcia-Quintanilla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Caspase signalling controls microglia activation and neurotoxicity</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">21389984</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupaul-Chicoine</surname><given-names>J</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name></person-group><article-title>A new path to IL-1beta production controlled by caspase-8</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>211</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">22344277</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urata</surname><given-names>Y</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Hirota</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>I</given-names></name><name><surname>Izumi</surname><given-names>G</given-names></name><name><surname>Takamura</surname><given-names>M</given-names></name><etal/></person-group><article-title>IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells</article-title><source>Am J Reprod Immunol</source><year>2014</year><volume>72</volume><fpage>496</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">24974860</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CL</given-names></name><name><surname>Llenos</surname><given-names>IC</given-names></name><name><surname>Dulay</surname><given-names>JR</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder</article-title><source>Brain Res</source><year>2006</year><volume>1073&#8211;1074</volume><fpage>25</fpage><lpage>37</lpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cousins</surname><given-names>DA</given-names></name><name><surname>Butts</surname><given-names>K</given-names></name><name><surname>Young</surname><given-names>AH</given-names></name></person-group><article-title>The role of dopamine in bipolar disorder</article-title><source>Bipolar Disord</source><year>2009</year><volume>11</volume><fpage>787</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">19922550</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Oberg</surname><given-names>H</given-names></name><name><surname>Mathe</surname><given-names>JM</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name></person-group><article-title>Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons</article-title><source>Amino Acids</source><year>2001</year><volume>20</volume><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">11452979</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Andersson</surname><given-names>AS</given-names></name><name><surname>Linderholm</surname><given-names>KR</given-names></name><name><surname>Holtze</surname><given-names>M</given-names></name><name><surname>Nilsson-Todd</surname><given-names>LK</given-names></name><name><surname>Schwieler</surname><given-names>L</given-names></name><etal/></person-group><article-title>Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia</article-title><source>Int J Neuropsychopharmacol</source><year>2009</year><volume>12</volume><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">18796185</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>B</given-names></name><name><surname>Jabben</surname><given-names>N</given-names></name><name><surname>Krabbendam</surname><given-names>L</given-names></name><name><surname>van Os</surname><given-names>J</given-names></name></person-group><article-title>Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives</article-title><source>Psychol Med</source><year>2008</year><volume>38</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">17922938</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>HM</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name></person-group><article-title>Treating impaired cognition in schizophrenia</article-title><source>Curr Pharm Biotechnol</source><year>2012</year><volume>13</volume><fpage>1587</fpage><lpage>1594</lpage><pub-id pub-id-type="pmid">22283754</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>V</given-names></name><name><surname>Lipina</surname><given-names>T</given-names></name><name><surname>Roder</surname><given-names>JC</given-names></name></person-group><article-title>Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia</article-title><source>Psychopharmacology</source><year>2008</year><volume>200</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">18597079</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikiforuk</surname><given-names>A</given-names></name><name><surname>Kos</surname><given-names>T</given-names></name><name><surname>Rafa</surname><given-names>D</given-names></name><name><surname>Behl</surname><given-names>B</given-names></name><name><surname>Bespalov</surname><given-names>A</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner</article-title><source>Neuropharmacology</source><year>2011</year><volume>61</volume><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">21530555</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name></person-group><article-title>Microglia: scapegoat, saboteur, or something else?</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">23307732</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><article-title>Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders</article-title><source>Curr Opin Neurobiol</source><year>2014</year><volume>27</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">24694749</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhre</surname><given-names>K</given-names></name><name><surname>Shin</surname><given-names>SY</given-names></name><name><surname>Petersen</surname><given-names>AK</given-names></name><name><surname>Mohney</surname><given-names>RP</given-names></name><name><surname>Meredith</surname><given-names>D</given-names></name><name><surname>Wagele</surname><given-names>B</given-names></name><etal/></person-group><article-title>Human metabolic individuality in biomedical and pharmaceutical research</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">21886157</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solovieff</surname><given-names>N</given-names></name><name><surname>Milton</surname><given-names>JN</given-names></name><name><surname>Hartley</surname><given-names>SW</given-names></name><name><surname>Sherva</surname><given-names>R</given-names></name><name><surname>Sebastiani</surname><given-names>P</given-names></name><name><surname>Dworkis</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5&#8242; olfactory receptor gene cluster</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>1815</fpage><lpage>1822</lpage><pub-id pub-id-type="pmid">20018918</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>SY</given-names></name><name><surname>Fauman</surname><given-names>EB</given-names></name><name><surname>Petersen</surname><given-names>AK</given-names></name><name><surname>Krumsiek</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>An atlas of genetic influences on human blood metabolites</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">24816252</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Cerebrospinal fluid (CSF) concentrations of interleukin-1&#946; (IL-1&#946;) in male euthymic bipolar disorder patients (data set I) and healthy controls. (<bold>a</bold>) Mean CSF IL-1&#946; concentration (&#177; s.e.m.) in 30 healthy male volunteers (0.79 &#177;0.044 pg ml<sup>&#8722;1</sup>), 16 bipolar disorder patients without a history of psychosis (3.06 &#177; 0.58 pg ml<sup>&#8722;1</sup>) and 11 bipolar patients with a history of psychosis 5.35 &#177; 0.71 pg ml<sup>&#8722;1</sup>. One-way analysis of variance (ANOVA) with Tukey&#8217;s <italic>post hoc</italic> tests, <italic>P</italic>&lt;1 &#215; 10<sup>&#8722;6</sup>; <italic>post hoc</italic> tests: controls vs nonpsychotic bipolar patients, <italic>P</italic> = 6 &#215; 10<sup>&#8722;5</sup>; controls vs psychotic bipolar patients, <italic>P</italic>&lt;1 &#215; 10<sup>&#8722;6</sup>; and nonpsychotic bipolar vs psychotic bipolar patients, <italic>P</italic> = 0.020. (<bold>b</bold>) Of these patients, 16 carried out the trail making test (TMT). Nine patients scored &#8805; 10 (mean standard score) and 7 scored &lt;10. The median CSF IL-1&#946; concentration was higher in the group with more difficulties in set-shifting (5.84 &#177; 2.89 pg ml<sup>&#8722;1</sup> (median &#177; interquartile range)) compared with the group that scored &#8805; 10 (1.96 &#177; 2.68 pg ml<sup>&#8722;1</sup>, Mann&#8211;Whitney <italic>U</italic>-test, <italic>P</italic> = 0.012). (<bold>c</bold>) A possible confounding effect of peripheral inflammation was assessed with correlation analyses. Increasing CSF IL-1&#946; concentration was associated with difficulties in set-shifting (<italic>r</italic><sub>s</sub> (Spearman) = &#8722; 0.53, <italic>P</italic> = 0.034), also when adjusting for high-sensitivity C-reactive protein (hsCRP) concentration (<italic>r</italic><sub>s</sub> = &#8722; 0.59, <italic>P</italic> = 0.021). Error bars represent mean &#177; s.e.m. in (<bold>a</bold>) and in (<bold>b</bold>) median with third quartile. Two-sided <italic>P</italic>-values, statistical significance set to <italic>P</italic>&lt;0.05. *<italic>P</italic>&lt;0.05, ****<italic>P</italic>&lt;0.0001.</p></caption><graphic xlink:href="nihms805086f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cerebrospinal fluid (CSF) concentrations of kynurenic acid (KYNA) in euthymic bipolar disorder (BD) patients (data set II) and healthy controls. (<bold>a</bold>) Mean CSF KYNA concentration (&#177; s.e.m.) in 46 healthy controls (1.60 &#177;0.10 nM), 40 bipolar patients without a history of psychosis (1.72 &#177; 0.12 nM) and 36 bipolar patients with a history of psychosis (2.08 &#177; 0.18 nM). One-way analysis of variance (ANOVA) with Tukey&#8217;s <italic>post hoc</italic> tests (using residuals from a linear regression of age vs CSF KYNA); <italic>P</italic> = 9 &#215; 10<sup>&#8722;3</sup>; <italic>post hoc</italic> tests: controls vs nonpsychotic bipolar patients, <italic>P</italic> = 0.99; controls vs psychotic bipolar patients, <italic>P</italic> = 0.015; and nonpsychotic bipolar vs psychotic bipolar patients, <italic>P</italic> = 0.026. (<bold>b</bold>) CSF KYNA (nM) in the 51 bipolar patients who underwent trail making test (TMT) from Delis&#8211;Kaplan Executive Function System (D-KEFS). The mean CSF KYNA concentration was significantly higher in patients who scored below the mean standard score (&lt;10, <italic>N</italic> = 26; 2.12 &#177; 0.12 nM) compared with patients scoring average or higher (&#8805;10, <italic>N</italic> = 25; 1.62 &#177; 0.21 nM, <italic>t</italic>-test: <italic>P</italic> = 0.048, Pearson&#8217;s <italic>r</italic> = 0.28; <italic>P</italic> = 0.045). (<bold>c</bold>) The correlation between CSF KYNA and CSF homovanillic acid (HVA) (nM) in 72 of these 76 patients. Pearson&#8217;s <italic>r</italic> = 0.67; <italic>P</italic> = 9 &#215; 10<sup>&#8722;11</sup>. (<bold>d</bold>) CSF HVA (nM) concentration in 72 bipolar patients with or without a history of psychosis in comparison with CSH HVA levels in 45 healthy controls. One-way ANOVA followed by Tukey&#8217;s <italic>post hoc</italic> tests revealed that the psychotic group had a significantly higher mean CSF HVA concentration (280 &#177; 14.4 nM) compared with controls (216 &#177; 10.6 nM, <italic>P</italic> = 3 &#215; 10<sup>&#8722;3</sup>) and nonpsychotic patients (227 &#177; 15.6 nM, <italic>P</italic> = 0.024), whereas no significant different in CSF HVA concentration was seen between controls and nonpsychotic patients (<italic>P</italic> = 0.81). CSF KYNA concentration was independent of BD subtype (BD-I: <italic>M</italic> = 1.97 &#177; 0.17 nM, <italic>N</italic> = 40; BD-II: <italic>M</italic> = 1.80 &#177; 0.13 nM, <italic>N</italic> = 36, <italic>P</italic> = 0.43), and did not differ by sex (<italic>M</italic> = 1.93 &#177; 0.15 nM among females (<italic>N</italic> = 46), and <italic>M</italic> = 1.82 &#177; 0.15 nM among males (<italic>N</italic> = 30), respectively, <italic>P</italic> = 0.63). All error bars represent s.e.m. Two-sided <italic>P</italic>-values, statistical significance set to <italic>P</italic>&lt;0.05. *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, NS, not significant.</p></caption><graphic xlink:href="nihms805086f2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Stimulation of fetal human cortical astrocytes with interleukin-1&#946; (IL-1&#946;) and interferon-&#947; (IFN-&#947;). Fetal cultured human cortical astrocytes stimulated with recombinant human IL-1&#946; (10 ng ml<sup>&#8722;1</sup>) and IFN-&#947; (200 ng ml<sup>&#8722;1</sup>), a prototypical indoleamine 2,3-dioxygenase 1 (IDO1) activator, as positive control. Protein levels of IDO1 and tryptophan 2,3-dioxygenase-2 (TDO2) analyzed at baseline and after exposure to IL-1&#946; or IFN-&#947; for 48 h. IDO and TDO immunopositive bands are normalized to &#946;-actin. Bar graphs here represent IDO1 and TDO2 protein levels expressed as % of vehicle-treated control cultures. All cells were analyzed for kynurenic acid (KYNA) at time points 1, 3 and 24 h. Bar graphs here represent % of vehicle (<italic>t</italic> = 1 h) at these time points. All data are reported as mean &#177; s.e.m. All experiments were performed in triplicate and repeated twice. Representative western blots of IDO1 and TDO2 are shown below each bar graph (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S7&#8211;S9</xref> for full size western blots). (<bold>a</bold>) Low levels of IDO1 protein expression were detected in unstimulated cells, but despite the marked increase of <italic>IDO1</italic> mRNA levels following IL-1&#946; stimulation, no changes in protein levels were observed after 48 h of IL-1&#946; exposure (90 &#177; 5.13% vs 100 &#177; 7.85%, <italic>P</italic> = 0.41). Stimulation with IFN-&#947; was associated with a marked increase in protein levels of IDO1 (1084 &#177; 117% vs 100 &#177; 7.85%, <italic>P</italic> = 0.001). (<bold>b</bold>) Stimulation with IL-1&#946; for 48 h increased protein levels of TDO2 compared with vehicle-treated cells (139 &#177; 11.1% vs 100 &#177; 2.70%, <italic>P</italic> = 0.006), whereas stimulation with IFN-&#947; did not affect protein levels of TDO2 (90 &#177; 11.2% vs 100 &#177; 8.70% <italic>P</italic> = 0.21). Immunofluorescent staining of IDO1 (<bold>c</bold>) protein visualized in green and TDO2 (<bold>d</bold>) protein visualized in red following 48 h of IL-1&#946; stimulation confirmed low levels of IDO protein in most cells and scattered cells expressing high levels of TDO2. Images captured at &#215; 40 magnification. Nuclear staining was performed using 4&#8242;,6-diamidino-2-phenylindole (DAPI). (<bold>e</bold>) At 24 h, cells stimulated with IFN-&#947; had more than 85 times higher KYNA concentrations (10.8 &#177; 0.34 nM) than vehicle-treated cells (0.14 &#177; 0.04 nM, <italic>P</italic>&lt;0.0001). (<bold>f</bold>) At 24 h, cells stimulated with IL-1&#946; showed 4 times higher KYNA concentrations (mean &#177; s.e.m.: 1.70 &#177; 0.11 nM) than vehicle-treated cells (0.42 &#177; 0.10 nM, <italic>p</italic>&lt;0.0001). Two-sided <italic>P</italic>-values, statistical significance set to <italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001.</p></caption><graphic xlink:href="nihms805086f3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Overview of the proposed sorting nexin 7 (SNX7)-mediated induction of the kynurenine pathway in bipolar disorder (BD). Downregulation of <italic>SNX7</italic> induces the degradation of the short form of c-FLIP that competitively inhibits the autocatalytic processing of pro-caspase-8 at the ripoptosome. This leads to increased levels of active caspase-8, resulting in the processing and secretion of interleukin-1&#946; (IL-1&#946;). IL-1&#946; subsequently induces the rate-limiting enzyme tryptophan 2,3-dioxygenase-2 (TDO2) in the kynurenine pathway, causing an elevation in brain kynurenic acid (KYNA) that, according to our clinical association data, leads to a persistent set-shifting impairment as well as to a dopaminergic dysregulation that evoke vulnerability for psychosis in bipolar disorder.</p></caption><graphic xlink:href="nihms805086f4"/></fig><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1</label><caption><p>Associations between the minor G allele in rs10158645, CSF concentration of KYNA, HVA and a history of psychosis in euthymic BD patients</p></caption><table-wrap-foot><fn id="TFN1"><p>Abbreviations: BD, bipolar disorder; CI, confidence interval; CSF, cerebrospinal fluid; HVA, homovanillic acid; IE, indirect effect; KYNA, kynurenic acid; MAF, minor allele frequency; OR, odds ratio. All reported <italic>P</italic>-values are two sided.</p></fn><fn id="TFN2"><label>a</label><p>IE = indirect effect for mediation. Non-parametric bootstrap method, the PROCESS script for SPSS (see <ext-link ext-link-type="uri" xlink:href="http://afhayes.com/spss-sas-and-mplus-macros-and-code.html">http://afhayes.com/spss-sas-and-mplus-macros-and-code.html</ext-link>). Causal variable = allele frequency in rs10158645, mediator = CSF KYNA concentration and outcome variable = CSF HVA concentration. Direct effect = 43 (&#8722;0.53 to 86).</p></fn><fn id="TFN3"><label>b</label><p>Causal variable = CSF KYNA concentration, mediator = CSF HVA concentration and outcome variable = psychosis (0/1). Direct effect = 0.15 (&#8722;0.61to 0.90).</p></fn><fn id="TFN4"><label>c</label><p>95% Bootstrap CI (percentile bootstrap = 20 000).</p></fn><fn id="TFN5"><label>d</label><p>Spearman&#8217;s coefficient.</p></fn><fn id="TFN6"><label>e</label><p>In sample I, only one patient was homozygous for the minor G allele in rs1018645 and the analysis was performed under an additive model. In sample II, 21 patients were homozygous for the minor G allele (18 with psychosis) and additional analyses under a recessive model was performed in sample II and the combined sample (I+II).</p></fn></table-wrap-foot></table-wrap></floats-group></article>